The TissueAb team seeks to enhance the technology that employs phage display libraries to identify tissues or cell type-specific antibodies (Ab) for targeted therapies. This technology will broadly apply to immune-oncology, autoimmunity, rare, and infectious diseases.
Dr. Lauren Williamson is a translational immunologist developing next-generation antibody therapeutics for infectious diseases, cancer, and autoimmunity. At Vanderbilt, she leads efforts in antibody discovery and engineering, with a focus on monoclonal and bispecific formats, expression optimization, and phage display technologies. Her research has contributed to candidate therapeutics targeting Zika, Ebola, influenza, and other high-impact pathogens.
She is also the founder of TissueAb, a novel in vivo screening platform for identifying tissue-targeting antibodies with broad potential in precision medicine. Supported by Vanderbilt’s Innovation Catalyst Fund, the platform exemplifies Dr. Williamson’s focus on translating immunological advances into real-world therapeutic solutions.